
(meth’ a done)
Diskets, Dolophine, Metadol-D (CAN), Metador (CAN), Methadone HCl, Intensol, Methadose, Methadose Sugarfree
PREGNANCY CATEGORY C
CONTROLLED SUBSTANCE C-II
Drug class
Opioid agonist analgesic
Therapeutic Actions
Acts as agonist at specific opioid receptors in the CNS to produce analgesia, euphoria, sedation; the receptors mediating these effects are thought to be the same as those mediating the effects of endogenous opioids (enkephalins, endorphins); when used in approved methadone maintenance programs, can substitute for heroin, other illicit opioids in patients who want to terminate a drug use.
Indications
Relief of severe pain not responsive to non-opioid analgesics
Detoxification and temporary maintenance treatment of opioid addiction (ineffective for relief of general anxiety)
Contraindications and Cautions
Contraindicated with hypersensitivity to opioids, diarrhea caused by poisoning (before toxins are eliminated), bronchial asthma, COPD, cor pulmonale, respiratory depression, anoxia, kyphoscoliosis, acute alcoholism, increased intracranial pressure, paralytic ileus.
Use cautiously with acute abdominal conditions, CV disease, supraventricular tachycardias, myxedema, seizure disorders, delirium tremens, cerebral arteriosclerosis, ulcerative colitis, fever, Addison disease, prostatic hypertrophy, urethral stricture, recent GI or GU surgery, toxic psychosis, pregnancy before labor (crosses placenta; neonatal withdrawal observed in infants born to drug-using mothers; safety in pregnancy before labor not established), labor or delivery (administration of opioids to mother can cause respiratory depression of neonate—risk greatest for premature neonates), renal or hepatic impairment, lactation.
Available Forms
Tablets—5, 10 mg; oral solution—5 mg/5 mL, 10 mg/5 mL; oral concentrate—10 mg/mL; injection—10 mg/mL; dispersible tablets—40 mg
Dosages
Oral methadone is approximately one-half as potent as parenteral methadone.
Adults
Relief of pain: 2.5–10 mg IM, subcutaneously, or PO every 8–12 hr as necessary. IM route is preferred to subcutaneous for repeated doses (subcutaneous use may cause local irritation). Individualize dosage; patients with excessively severe pain and those who have become tolerant to the analgesic effect of opioids may need higher dosage.
Detoxification: Initially, 20–30 mg PO or parenteral; PO preferred. Increase dose to suppress withdrawal signs. 40 mg/day in single or divided doses is usually an adequate stabilizing dose for those physically dependent on high doses. Continue stabilizing doses for 2–3 days, then gradually decrease dosage every day or every 2 days. A daily reduction of 20% of the total dose may be tolerated. Provide sufficient dosage to keep withdrawal symptoms at tolerable level. Treatment should not exceed 21 days and may not be repeated earlier than 4 wk after completion of previous course. Detoxification treatment continued longer than 21 days becomes maintenance treatment, which may be undertaken only by approved programs (addicts hospitalized for other
medical conditions may receive methadone maintenance treatment).
Maintenance treatment: For patients who had been heavy heroin users up until hospital admission, initial dose of 20 mg PO 4–8 hr after heroin is stopped or 40 mg in a single dose PO. For patients with little or no opioid tolerance, half this dose may suffice. Dosage should suppress withdrawal symptoms but not produce acute opioid effects of sedation, respiratory depression. Give additional 10-mg doses if needed to suppress withdrawal syndrome. Adjust dosage, up to 120 mg/day.Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree